Stem Cell Therapeutics Corp. Announces That Dr. Allen Davidoff Will Present at the 2009 Neural Restoration Workshop Series
13 November 2009 - 1:00AM
Marketwired
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT") announced
that Dr. Allen Davidoff, Vice President of Product Development,
will be presenting at the 2009 Neural Regeneration Workshop taking
place in Albuquerque, New Mexico at the Sandia National
Laboratories, a U.S. Government facility. Dr. Davidoff will be
discussing "A drug based approach to Neurogenesis and recovery
after acute neurologic injury".
Dr. Alan Moore, President and CEO of SCT, commented as
follows:
"One of the key objectives of this workshop series is to
discover treatments that restore lost or damaged brain tissue in
order to support function recovery, specifically relating to
traumatic brain injury developed in combat. We feel this is an
ideal platform to discuss just how our stroke and traumatic brain
injury regimens have the capability to regenerate brain tissue and
return functionality."
About the November 2009 Neural Restoration Workshop Series:
Sandia National Laboratories and the Center for Neurotechnology
Studies of the Potomac Institute for Policy Studies will be hosting
a workshop series to gather information on the restoration of
neural function through treatments involving replacement of injured
and diseased brain tissue. Two parallel workshops are being be
held, the first was in Washington DC on November 4, 2009; and the
second in Albuquerque, NM on November 12, 2009. The objective of
these workshops is to assess the scientific and technical
state-of-the-art treatments and chart a path of research and
development leading to innovation in the treatment of brain injury
and disease through restoration of neural tissue.
Existing treatment options focus largely upon return to function
by adapting existing brain tissue to the best extent possible. Yet,
none of the current treatment options seek to restore lost or
damaged tissue to enable a return to function. There have been
substantial advances across various disciplines that offer the
potential for major innovations in the treatment of brain injury
and disease, and that focused research and development may result
in significant progress in this field.
In light of this, the goals of these workshops are to: (a) pulse
researchers from academia, industry and government to determine the
state of the art in the differentiation of neural cell types,
cultivation of neural tissue, neural circuit engineering,
integration of transplanted tissue with functional circuits, and
mechanisms for promoting functional recovery of injured or diseased
brain tissue; (b) identify key scientific and technical gaps and/or
limitations; and (c) delineate opportunities for advancing the
requisite science and technology toward achieving these goals.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a public biotechnology company (TSX VENTURE: SSS) focused on the
development and commercialization of drug-based therapies to treat
central nervous system diseases. SCT is a leader in the development
of therapies that utilize drugs to stimulate a patient's own
resident stem cells. The Company's programs aim to repair brain and
nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as traumatic brain
injury, multiple sclerosis, Huntington's disease, Alzheimer's
disease, and ALS.
For further information on Stem Cell Therapeutics Corp., visit
www.stemcellthera.com.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO 403-245-5495 ext.224 Email: amoore@stemcellthera.com Stem
Cell Therapeutics Corp. Chloe Douglas-Crampton Investor Relations
403-245-5495 ext. 221 Email: crampton@stemcellthera.com Website:
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024